SEATTLE, WA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)ACCESS TO ADVANCED HEALTH INSTITUTE, founded in 1993, is a mid-sized nonprofit in the Medical Research sector that reported $22.8M in total revenue in fiscal year 2023. Revenue fell 56% from the prior year — a significant decline worth monitoring.
AAHI IS A NONPROFIT BIOTECH RESEARCH INSTITUTE, BRINGING TOGETHER THE BEST EXPERTS, TECHNOLOGIES, AND PLATFORMS TO CREATE ACCESSIBLE, HIGH-QUALITY PRODUCTS AND SOLUTIONS FOR HARNESSING THE IMMUNE SYSTEM TO ALLEVIATE DISEASE.
FORMULATIONS - ADJUVANTS ARE POWERFUL IMMUNE-STIMULATING MOLECULES THAT INCREASE THE EFFICACY OF VACCINES AND ENHANCE THE IMMUNE SYSTEM'S ABILITY TO DESTROY TUMORS. AAHI HAS AMONG THE LARGEST...
FORMULATIONS - ADJUVANTS ARE POWERFUL IMMUNE-STIMULATING MOLECULES THAT INCREASE THE EFFICACY OF VACCINES AND ENHANCE THE IMMUNE SYSTEM'S ABILITY TO DESTROY TUMORS. AAHI HAS AMONG THE LARGEST PORTFOLIOS OF ADJUVANTS; IMPORTANTLY, AAHI SCIENTISTS FORMULATE THESE MOLECULES IN A WAY THAT MAKES THEM MINIMALLY TOXIC AND MAXIMALLY POTENT. IN PARTNERSHIP WITH VACCINE DEVELOPERS ACROSS THE WORLD, MANY AAHI ADJUVANT FORMULATIONS HAVE BEEN SAFELY ADMINISTERED TO THOUSANDS OF PEOPLE IN RIGOROUS CLINICAL TRIALS. AAHI'S ADJUVANT FORMULATIONS NOW ARE IN LEADING VACCINE CANDIDATES AGAINST HIV, TUBERCULOSIS, MALARIA, AND A MYRIAD OF OTHER INFECTIOUS DISEASES.
MANUFACTURING AND CLINICAL SUPPORT - AAHI'S IN-HOUSE MANUFACTURING CAPABILITIES SUPPORT RAPID SCALE-UP AND PRODUCTION OF VACCINES FOR USE IN PHASE 1 AND PHASE 2 CLINICAL TRIALS AND COMPLETE AAHIS'S...
MANUFACTURING AND CLINICAL SUPPORT - AAHI'S IN-HOUSE MANUFACTURING CAPABILITIES SUPPORT RAPID SCALE-UP AND PRODUCTION OF VACCINES FOR USE IN PHASE 1 AND PHASE 2 CLINICAL TRIALS AND COMPLETE AAHIS'S UNIQUE VACCINE DISCOVERY-DEVELOPMENT PROCESS. AAHI'S RESEARCH SCIENTISTS AND FORMULATIONS/PROCESS DEVELOPMENT TEAMS WORK WITH AAHI'S MANUFACTURING EXPERTS TO DEVELOP MANUFACTURING PROCESSES TO PRODUCE VACCINE CANDIDATES UNDER CONTROLLED CONDITIONS SO THATTHEY ARE SUITABLE FOR USE IN HUMAN STUDIES. THIS ENABLES AAHI TO QUICKLY AND EFFICIENTLY MOVE A VACCINE FROM LATE-STAGE RESEARCH TO EARLY PHASE CLINICAL STUDIES. AAHI CONSULTS LATER STAGE CLINICAL STUDIES. AAHI'S MANUFACTURING SUITE FOLLOWS US FDA "GOOD MANUFACTURING PRACTICE" REGULATIONS AND IS AN INVALUABLE RESOURCE TO AAHI SCIENTISTS AND BIOTECHNOLOGY DEVELOPERS IN THE NON-PROFIT, ACADEMIC, AND FORPROFIT SECTORS.
RNA VACCINES - RNA VACCINES HAVE BEEN SHOWN TO BE CRITICAL TOOLS FOR COMBATTING PANDEMICS AND HAVE BEEN SAFELY ADMINISTERED TO BILLIONS OF PEOPLE ACROSS THE GLOBE. AAHI'S RNA VACCINE PLATFORM IS...
RNA VACCINES - RNA VACCINES HAVE BEEN SHOWN TO BE CRITICAL TOOLS FOR COMBATTING PANDEMICS AND HAVE BEEN SAFELY ADMINISTERED TO BILLIONS OF PEOPLE ACROSS THE GLOBE. AAHI'S RNA VACCINE PLATFORM IS DISTINCT FROM EXISTING LICENSED RNA VACCINES IN THAT IT IS BASED ON A SELF-AMPLIFYING RNA TECHNOLOGY AND DELIVERED BY A FLEXIBLE NANOSTRUCTURED LIPID CARRIER. TOGETHER, THESE FEATURES MEAN THAT THE VACCINE COULD BE STOCKPILED FOR YEARS, DELIVERED AT ROOM TEMPERATURE, AND MORE RAPIDLY MANUFACTURED TO ADDRESS FUTURE PANDEMICS. AAHI SCIENTISTS ARE ADVANCING RNA VACCINES AGAINST COVID-19, INFLUENZA, YELLOW FEVER, ZIKA, CHIKUNGUNYA, AND HIV, AND ADAPTING THE PLATFORM TO BE DELIVERED BY NASAL SPRAY OR DIRECTLY ADMINISTERED INTO TUMORS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $22,776,375 | $51,186,254 | -0.6% |
| Expenses | $23,815,865 | $21,362,457 | +0.1% |
| Net Income | $-1,039,490 | $29,823,797 | -1.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| COREY CASPER | CEO, PRESIDENT | 40.00 |
Officer
Director
|
$542,213 | $41,463 | $583,676 |
| PATRICK SOON-SHIONG | BOARD CHAIR | 0.50 |
Officer
Director
|
$0 | $0 | $0 |
| DAVID KERR | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $0 |
| EDWARD MOCARSKI | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $0 |
| EDWARD HSU | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $0 |
| GLENDA GRAY | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $0 |
| RAOUL CONCEPCION | BOARD MEMBER | 0.50 |
Director
|
$0 | $0 | $0 |
| CANDICE DECAIRE | CHIEF STRATEGY OFFICER, SECRETARY | 40.00 |
Officer
|
$348,290 | $40,791 | $389,081 |
| JERRY KUO | CFOO, V.P. & TREASURER | 40.00 |
Officer
|
$344,534 | $55,747 | $400,281 |
| ANNA MARIE BECKMANN | EVP, PRODUCT DEVELOPMENT | 40.00 |
Key Emp
|
$280,027 | $42,086 | $322,113 |
| CHRISTOPHER FOX | SENIOR VP OF FORMULATIONS | 32.00 |
Key Emp
|
$236,068 | $55,214 | $291,282 |
| LINDA HAWKINS | SENIOR DIR. QUALITY ASSURANCE | 40.00 |
Key Emp
|
$228,348 | $40,634 | $268,982 |
| ROBRICK SMITH | DIRECTOR, INFORMATION TECHNOLOGY | 40.00 |
Key Emp
|
$192,601 | $46,265 | $238,866 |
| SUZAN SNODGRASS | DIRECTOR, FINANCE | 40.00 |
Key Emp
|
$184,714 | $33,380 | $218,094 |
| ANDREW JOHNSON | ASSOCIATE DIRECTOR, PROGRAM MGMT | 40.00 |
Key Emp
|
$176,746 | $23,630 | $200,376 |
| DARREN KLEMKOW | DIR. FACILITIES & PROCUREMENT | 40.00 |
Key Emp
|
$167,930 | $22,557 | $190,487 |
| EMILY VOIGT | DIR. RNA PROGRAM | 40.00 |
Key Emp
|
$166,818 | $42,091 | $208,909 |
| LISA MCNEILL | DIR. MANUFACTURING | 36.00 |
Key Emp
|
$162,652 | $33,698 | $196,350 |
| LISA BOUCHARD | DIR. QUALITY CONTROL | 40.00 |
Key Emp
|
$156,372 | $31,035 | $187,407 |
| JEFFREY GUDERIAN | DIR. LABORATORY MANAGEMENT | 40.00 |
Key Emp
|
$154,096 | $31,704 | $185,800 |
| ZACHARY SAGAWA | DIR. CLINICAL RESEARCH & REG. AFFAIRS | 40.00 |
Key Emp
|
$153,333 | $35,414 | $188,747 |
| DAMON PANG | SENIOR CORPORATE COUNSEL | 40.00 |
Highest
|
$133,466 | $34,084 | $167,550 |
| CRISTINA GOMAN | CLINICAL TRIAL MANAGER | 40.00 |
Highest
|
$129,357 | $9,837 | $139,194 |
| ROBERT KINSEY | SENIOR MANAGER, FORMULATIONS | 40.00 |
Highest
|
$126,960 | $20,533 | $147,493 |
| AMY SEMENOV | DIR. HUMAN RESOURCES | 40.00 |
Highest
|
$124,625 | $36,039 | $160,664 |
| THERESA BRITSCHGI | SENIOR PROJECT MANAGER | 40.00 |
Highest
|
$124,110 | $20,445 | $144,555 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2024 | No data | No data | No data | No data |
| 2023 | $22,776,375 | $23,815,865 | $39,831,178 | $-1,039,490 |
| 2022 | $51,186,254 | $21,362,457 | $42,840,477 | $29,823,797 |
| 2021 | $25,258,154 | $22,297,762 | $16,228,599 | $2,960,392 |
| 2020 | $13,342,560 | $19,814,751 | $13,563,097 | $-6,472,191 |
| 2019 | $21,976,016 | $29,046,899 | $16,784,379 | $-7,070,883 |
| 2018 | $28,954,130 | $29,001,021 | $28,838,131 | $-46,891 |
Compare ACCESS TO ADVANCED HEALTH INSTITUTE with other nonprofits in Washington and across the country.